Hospital
Cobre Valley Regional Medical Center
Cobre Valley Regional Medical Center was paid $32.11M by Medicaid between Jan 2018 and Dec 2024, across 265 billing codes. Its largest line is 99283, emergency room visit (moderate) — 26% of everything it billed.
33Billing provider infoCOBRE VALLEY REGIONAL MEDICAL CENTER
GLOBE, AZ 85501
GLOBE, AZ 85501
33aNPI1871566521assigned 02/10/2006
33bProvider typeCritical Access Hospital
28Total paid$32.11M
24GClaims611,795
24DCodes billed265
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Arizona
Rank by total paid#3 of 15
Median peer was paid$6.92M
This provider vs. median4.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 83,322 | $3.96M | |
| 2019 | 95,996 | $4.87M | |
| 2020 | 85,183 | $4.20M | |
| 2021 | 96,812 | $4.36M | |
| 2022 | 95,692 | $5.65M | |
| 2023 | 88,123 | $5.11M | |
| 2024incomplete | 66,667 | $3.95M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 26% | 25,188 | 22,577 | $8.36M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 17% | 8,325 | 7,535 | $5.59M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 10% | 6,823 | 6,347 | $3.27M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.2% | 9,526 | 8,713 | $1.69M |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 5.2% | 9,483 | 5,928 | $1.67M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.4% | 2,464 | 2,356 | $1.09M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 3.2% | 493 | 483 | $1.03M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.6% | 2,142 | 2,021 | $825K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.1% | 3,330 | 3,136 | $680K |
| 59025 | Fetal non-stress test | 1.8% | 2,888 | 1,447 | $574K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.3% | 913 | 865 | $425K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.3% | 1,124 | 1,083 | $423K |
253 more codes
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 656 | $298K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,569 | $298K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 11,940 | $297K |
| G0378 | Hospital observation service, per hour | <1% | 9,089 | $296K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 326 | $296K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 657 | $272K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,743 | $271K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 692 | $269K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 4,519 | $244K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 13,686 | $241K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 195 | $240K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 5,537 | $209K |
| 47563 | <1% | 25 | $199K | |
| 97161 | <1% | 1,351 | $161K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,189 | $153K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,418 | $150K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,785 | $149K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 9,409 | $130K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,625 | $119K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 796 | $104K |
| 73630 | <1% | 2,174 | $88K | |
| 73610 | <1% | 1,836 | $85K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 561 | $85K |
| 73030 | <1% | 1,396 | $78K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 711 | $77K |
| 73562 | <1% | 1,547 | $77K | |
| 73110 | <1% | 1,219 | $70K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,500 | $68K |
| 93971 | <1% | 354 | $66K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,022 | $66K |
| 80053 | Comprehensive metabolic panel | <1% | 29,706 | $64K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 10,253 | $63K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,378 | $63K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,764 | $62K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 852 | $54K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,786 | $54K |
| 73130 | <1% | 1,354 | $54K | |
| 84702 | <1% | 1,732 | $48K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,315 | $47K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 14,625 | $42K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 9,436 | $42K |
| 72110 | <1% | 329 | $40K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 994 | $39K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,644 | $39K |
| 97162 | <1% | 259 | $33K | |
| 80061 | Lipid panel | <1% | 5,259 | $32K |
| 94762 | <1% | 4,501 | $32K | |
| 87806 | <1% | 1,188 | $31K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 4,374 | $30K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 244 | $27K |
| 73502 | <1% | 573 | $26K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,008 | $25K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 25 | $22K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 33,169 | $21K |
| 96376 | <1% | 3,206 | $20K | |
| 83880 | <1% | 2,095 | $16K | |
| 87186 | <1% | 3,098 | $15K | |
| 76801 | <1% | 174 | $14K | |
| 72100 | <1% | 127 | $14K | |
| 0011A | <1% | 676 | $14K | |
| 87653 | <1% | 347 | $13K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 73 | $12K |
| 82728 | <1% | 686 | $11K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,666 | $11K |
| 82607 | <1% | 1,614 | $10K | |
| 74018 | <1% | 276 | $10K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 40 | $9K |
| 71045 | Radiologic examination, chest; single view | <1% | 8,734 | $9K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,214 | $9K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,322 | $8K |
| 84403 | <1% | 148 | $8K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,889 | $7K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,435 | $7K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,753 | $7K |
| 73560 | <1% | 137 | $7K | |
| 87632 | <1% | 120 | $7K | |
| 73080 | <1% | 140 | $6K | |
| 36000 | <1% | 3,296 | $6K | |
| 84152 | <1% | 105 | $5K | |
| 87490 | <1% | 330 | $5K | |
| 93970 | <1% | 13 | $4K | |
| 96367 | <1% | 1,248 | $4K | |
| 71250 | <1% | 34 | $3K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,635 | $3K |
| 86001 | <1% | 13 | $3K | |
| 86850 | <1% | 1,403 | $3K | |
| 72050 | <1% | 13 | $3K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 19 | $3K |
| 73590 | <1% | 82 | $2K | |
| 76830 | Ultrasound, transvaginal | <1% | 29 | $2K |
| 72131 | <1% | 13 | $2K | |
| 85027 | <1% | 3,825 | $2K | |
| 72170 | <1% | 26 | $2K | |
| 94760 | <1% | 32,970 | $2K | |
| 59051 | <1% | 2,704 | $2K | |
| 93015 | <1% | 417 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 13,006 | $2K |
| 12001 | <1% | 74 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 24,378 | $2K |
| 76536 | <1% | 12 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 686 | $2K |
| 93229 | <1% | 435 | $2K | |
| 84030 | <1% | 150 | $2K | |
| 87070 | <1% | 780 | $1K | |
| 36592 | <1% | 6,549 | $1K | |
| 81001 | <1% | 15,937 | $1K | |
| 0064A | <1% | 32 | $1K | |
| 85379 | <1% | 1,826 | $1K | |
| 70486 | <1% | 53 | $1K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 405 | $1K |
| 87075 | <1% | 300 | $1K | |
| 83013 | <1% | 14 | $986.47 | |
| 76770 | <1% | 12 | $966.42 | |
| 73140 | <1% | 38 | $938.38 | |
| 85730 | <1% | 3,256 | $907.16 | |
| 84703 | <1% | 6,161 | $781.52 | |
| 87280 | <1% | 348 | $747.46 | |
| 87210 | <1% | 492 | $742.80 | |
| 85610 | <1% | 4,557 | $727.15 | |
| 84144 | <1% | 481 | $700.33 | |
| 87634 | <1% | 461 | $691.03 | |
| 86757 | <1% | 14 | $587.42 | |
| 83690 | <1% | 5,974 | $578.26 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 29 | $525.49 |
| 77080 | <1% | 12 | $519.12 | |
| 80074 | <1% | 83 | $489.13 | |
| 86592 | <1% | 1,874 | $484.30 | |
| 82570 | <1% | 1,307 | $455.84 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 923 | $435.29 |
| 82248 | <1% | 36 | $415.44 | |
| 85014 | <1% | 25 | $385.90 | |
| 86140 | <1% | 1,005 | $351.49 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 234 | $342.19 |
| 87040 | <1% | 2,008 | $338.08 | |
| 86803 | <1% | 940 | $337.26 | |
| 80076 | <1% | 219 | $323.53 | |
| 99152 | <1% | 78 | $313.76 | |
| 84550 | <1% | 676 | $278.54 | |
| 83550 | <1% | 373 | $277.51 | |
| 82746 | <1% | 140 | $266.20 | |
| 83540 | <1% | 653 | $234.79 | |
| 84484 | <1% | 7,434 | $230.13 | |
| 86769 | <1% | 19 | $228.25 | |
| 82670 | <1% | 19 | $188.61 | |
| 82043 | <1% | 675 | $181.13 | |
| 76998 | <1% | 79 | $141.68 | |
| 80320 | <1% | 2,820 | $134.37 | |
| 86762 | <1% | 231 | $122.11 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,783 | $118.09 |
| 83655 | <1% | 195 | $101.32 | |
| 83735 | <1% | 4,598 | $95.16 | |
| 82784 | <1% | 24 | $85.43 | |
| 84153 | <1% | 69 | $81.40 | |
| 85652 | <1% | 1,368 | $78.81 | |
| 84436 | <1% | 1,839 | $72.58 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,196 | $70.70 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,216 | $66.48 |
| 82950 | <1% | 55 | $65.08 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 122 | $62.33 |
| 87081 | <1% | 388 | $55.89 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,029 | $49.29 |
| 86039 | <1% | 178 | $48.61 | |
| 82962 | <1% | 8,580 | $36.15 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,221 | $35.00 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,596 | $33.00 |
| 86900 | <1% | 1,749 | $31.80 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,731 | $31.53 |
| 87340 | <1% | 901 | $30.65 | |
| 84439 | <1% | 2,224 | $20.03 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,552 | $18.18 |
| J2704 | Injection, propofol, 10 mg | <1% | 4,394 | $15.18 |
| 80349 | <1% | 843 | $14.22 | |
| 83605 | <1% | 2,627 | $14.13 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 557 | $13.38 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,011 | $12.33 |
| 82550 | <1% | 405 | $10.39 | |
| 94761 | <1% | 2,382 | $7.33 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 88 | $6.51 |
| 84156 | <1% | 59 | $4.01 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 1,183 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 182 | $0.00 |
| 80329 | 0% | 1,127 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 4,742 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 2,512 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 713 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 354 | $0.00 |
| 87590 | 0% | 330 | $0.00 | |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 269 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 241 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 286 | $0.00 |
| 96368 | 0% | 1,217 | $0.00 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 0% | 131 | $0.00 |
| 84154 | 0% | 53 | $0.00 | |
| 97010 | 0% | 23 | $0.00 | |
| 85018 | 0% | 25 | $0.00 | |
| 99153 | Mod sedat endo service >5yrs | 0% | 13 | $0.00 |
| 82150 | 0% | 95 | $0.00 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 70 | $0.00 |
| 83615 | 0% | 55 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 51 | $0.00 |
| 0012A | 0% | 29 | $0.00 | |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | 0% | 29 | $0.00 |
| 82803 | 0% | 12 | $0.00 | |
| Q0240 | Injection, casirivimab and imdevimab, 600 mg | 0% | 30 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 17 | $0.00 |
| 92551 | 0% | 13 | $0.00 | |
| J3490 | Unclassified drugs | 0% | 17 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 58 | $0.00 |
| 83014 | 0% | 13 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 785 | $0.00 |
| G0168 | Wound closure utilizing tissue adhesive(s) only | 0% | 67 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 1,571 | $0.00 |
| Q9958 | High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml | 0% | 380 | $0.00 |
| 81002 | 0% | 444 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 704 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 452 | $0.00 |
| 84100 | 0% | 29 | $0.00 | |
| 86431 | 0% | 66 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 74 | $0.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 52 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 61 | $0.00 |
| 74300 | 0% | 39 | $0.00 | |
| 86787 | 0% | 254 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 278 | $0.00 |
| 90715 | 0% | 297 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 350 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 59 | $0.00 |
| 80326 | 0% | 184 | $0.00 | |
| G0511 | Rural health clinic or federally qualified health center (rhc or fqhc) only, general care management, 20 minutes or more of clinical staff time for chronic care management services or behavioral health integration services directed by an rhc or fqhc practitioner (physician, np, pa, or cnm), per calendar month | 0% | 92 | $0.00 |
| 86705 | 0% | 25 | $0.00 | |
| 29125 | 0% | 104 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 27 | $0.00 |
| 93224 | 0% | 96 | $0.00 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 0% | 148 | $0.00 |
| 84481 | 0% | 162 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 133 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 64 | $0.00 |
| 24241 | 0% | 27 | $0.00 | |
| 82247 | 0% | 35 | $0.00 | |
| 99173 | 0% | 12 | $0.00 | |
| 76000 | 0% | 14 | $0.00 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 133 | $0.00 |
| 90472 | Immunization administration, each additional vaccine (list separately) | 0% | 46 | $0.00 |
| 76942 | 0% | 12 | $0.00 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 0% | 12 | $0.00 |
| A4314 | Insertion tray with drainage bag with indwelling catheter, foley type, two-way latex with coating (teflon, silicone, silicone elastomer or hydrophilic, etc.) | 0% | 13 | $0.00 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 75 | $0.00 |
| 10060 | 0% | 14 | $0.00 | |
| 86038 | 0% | 13 | $0.00 | |
| 86709 | 0% | 13 | $0.00 | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 0% | 13 | $0.00 |
| 86200 | 0% | 13 | $0.00 | |
| 97116 | 0% | 21 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJENSEN, NEAL (CFO)
| Provider | Location | Paid |
|---|---|---|
| Cobre Valley Regional Medical Center | Globe, AZ | $10.76M |
| Cobre Valley Regional Medical Center | Superior, AZ | $3.00M |
| Cobre Valley Regional Medical Center | Globe, AZ | $2.70M |
| Cobre Valley Regional Medical Center | Tonto Basin, AZ | $159K |
| Cobre Valley Regional Medical Center | Young, AZ | $10K |
| Cobre Valley Regional Medical Center | Globe, AZ | $5K |
| Cobre Valley Regional Medical Center | Globe, AZ | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.